Share on StockTwits

Shares of C.R. Bard (NYSE:BCR) have received an average rating of “Hold” from the twenty ratings firms that are currently covering the stock, AnalystRatingsNetwork.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $138.94.

Shares of C.R. Bard (NYSE:BCR) traded up 0.73% on Tuesday, hitting $141.72. 194,873 shares of the company’s stock traded hands. C.R. Bard has a 52 week low of $106.72 and a 52 week high of $150.13. The stock’s 50-day moving average is $144.1 and its 200-day moving average is $139.7. The company has a market cap of $10.807 billion and a price-to-earnings ratio of 15.28.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.06. The company had revenue of $799.30 million for the quarter, compared to the consensus estimate of $787.10 million. During the same quarter in the previous year, the company posted $1.44 earnings per share. The company’s revenue for the quarter was up 8.0% on a year-over-year basis. On average, analysts predict that C.R. Bard will post $8.21 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Friday, August 1st. Investors of record on Monday, July 21st will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend is Thursday, July 17th. This is an increase from C.R. Bard’s previous quarterly dividend of $0.21.

A number of research firms have recently commented on BCR. Analysts at S&P Equity Research downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Friday. They now have a $150.00 price target on the stock, up previously from $145.00. Separately, analysts at Barclays downgraded shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, June 18th. They now have a $150.00 price target on the stock, down previously from $155.00. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of C.R. Bard in a research note on Friday, June 13th. They now have a $146.00 price target on the stock, up previously from $138.00.

C. R. Bard, Inc (NYSE:BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.